224 related articles for article (PubMed ID: 34131894)
21. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
22. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
Cosenza M; Sacchi S; Pozzi S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299273
[TBL] [Abstract][Full Text] [Related]
23. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
24. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
25. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
26. CAR T therapy beyond cancer: the evolution of a living drug.
Baker DJ; Arany Z; Baur JA; Epstein JA; June CH
Nature; 2023 Jul; 619(7971):707-715. PubMed ID: 37495877
[TBL] [Abstract][Full Text] [Related]
27. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
28. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
29. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
30. CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.
Slaney CY; Wang P; Darcy PK; Kershaw MH
Cancer Discov; 2018 Aug; 8(8):924-934. PubMed ID: 30012854
[TBL] [Abstract][Full Text] [Related]
31. T lymphocytes as therapeutic arsenal for patients with hematological malignancies.
Montoro J; PiƱana JL; Sanz J; Guerreiro M
Curr Opin Oncol; 2018 Nov; 30(6):425-434. PubMed ID: 30124521
[TBL] [Abstract][Full Text] [Related]
32. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
33. Adoptive T cell therapy: Boosting the immune system to fight cancer.
Leon E; Ranganathan R; Savoldo B
Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066
[TBL] [Abstract][Full Text] [Related]
34. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
35. Next-generation CAR T cells to overcome current drawbacks.
Lundh S; Maji S; Melenhorst JJ
Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
[TBL] [Abstract][Full Text] [Related]
36. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
Azizi AA; Pillai M; Thistlethwaite FC
Curr Opin Oncol; 2019 Sep; 31(5):430-438. PubMed ID: 31335828
[TBL] [Abstract][Full Text] [Related]
37. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
38. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells.
Sanber K; Savani B; Jain T
Br J Haematol; 2021 Dec; 195(5):660-668. PubMed ID: 34036558
[TBL] [Abstract][Full Text] [Related]
39. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Holstein SA; Lunning MA
Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
[TBL] [Abstract][Full Text] [Related]
40. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]